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We investigated the relationship between asthma mortality and long-acting beta2-agonists
(LABA), including interactions with age, inhaled corticosteroids (ICS) and social deprivation.
We used a new, expanded dataset of recorded medication extracted blind from the anon-
ymised primary care records of an earlier British case-control study. The cases were 532
asthma deaths aged < 65 occurring between 1994 and 1998 and the controls were 532 asthma
admissions, matched for age, hospital, and index date (date of death/asthma admission). The
exposure periods prior to the index date were current ( 2 months) or recent ( > 2e6 months).
We found no evidence of an overall association with current (OR Z 0.89 [95% confidence
interval 0.61e1.30]) or recent (1.08 [0.76e1.53]) mention of LABA, but there was some
evidence of a positive interaction with age. Among controls with mention of LABA, a concurrent
mention of ICS (within 1 month) was common (85% and 93% for the two respective periods)
which limited our power to investigate any interaction between LABA and ICS. There was no
coherent evidence of effect modification by social deprivation.
In a population based case-control study where prescription of LABA without concomitant
ICS was uncommon there was no evidence of an overall association between LABA and asthma
death.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Concerns that the prescription of inhaled long-acting beta2-
agonists (LABA) might be associated with a higher risk of8725 5493; fax: þ44 20 8725
.uk (B.K. Butland).
0 Elsevier Ltd. All rights reservedasthma death were first raised by Castle et al. in 1993.1More
recently the SMART trial2e4 found evidence of an increased
risk of asthma related death, and ‘combined asthma related
death or life threatening experiences’ among those in the
Salmeterol versus the placebo group. For both outcomes the
increase was possibly tempered by concomitant use of
inhaled corticosteroids (ICS) and for ‘combined asthma
related death or life threatening experiences’, the increase
was largely confined to African-Americans.2,3.
550 B.K. Butland et al.The original analysis of the ADCCS (Asthma Death Case-
Control Study5e7) found no evidence of an adverse effect of
LABA whether mentioned in the primary care record in the 3
months,> 3e12months, or> 1e5 years before the index date
(date of death for cases and date of hospital admission for
controls). Mention of SABA in the > 1e5 years prior was asso-
ciated with a higher risk of asthma death while mentions of
antibiotics in the 3 months and > 1e5 years prior and oral
corticosteroids in the 3 months prior were associated with
a lower risk of asthma death.5,7 However, this analysis had
certain limitations 1) potential biases were noted which may
have influenced case-control comparisons, particularly in the
3 months prior to index date 2) there was no analysis of the
interactionbetweenLABAand ICSand3) therewas noattempt
to examine interactions with socioeconomic deprivation.
We have conducted a new, more detailed and quality
controlled extraction from the original records and made
adjustments for potential biases. Using this dataset, we aim to
investigate theassociationbetweenasthmadeathandmention
of LABA in the 2 and > 2e6 months prior to index date and to
consider as possible modifying effects, age, concomitant
prescribing with ICS and a socioeconomic deprivation index.
Materials and methods
Study subjects and design
Full details aredescribed in earlier publications.5e7 The study
areas were based on regions participating in confidential
inquiries into asthma deaths and covered 27% of the British
population (a population in which medical care is provided
free of charge at the point of delivery). The case series
comprised all asthma deaths aged< 65 years occurring in the
study areas of England and Wales between 1994 and 1998
inclusive and in the study areas of Scotland between 1996 and
1998 inclusive. Fixed dose ICS/LABA combination inhalers
were not prescribed during the period covered by the study.
All cases had ‘asthma’ in part 1 of the death certificate
with no more credible non-respiratory underlying cause.
After exclusions (detailed elsewhere6,7), 532 cases were
included in the study. For each case, one control was
selected from the asthma discharge list of the hospital
where the case had died (or the next nearest hospital or,
for a community death, the hospital to which the case
would have been admitted). The control was selected
firstly to have a similar index date to its case (96% within 6
months, maximum difference 13 months) and secondly to
be of a similar age (98% within 5 years, maximum age
difference 12 years).6,7 For each case and control, their
primary care record was first anonymised and then photo-
copied for the 5 years prior to the index date.5e7
The Asthma Death Case-Control Study was approved by
the South Thames Multi-centre Research Ethics Committee
(MREC) in September 1997. Permissions to photocopy ano-
nymised primary care records were obtained in writing from
general practitioners.
Methods
Using thesephotocopied records, nursing/medically qualified
personnel conducted a new and more detailed extraction ofdata on drugs, COPD (i.e. mention of COPD, COAD, chronic
bronchitis and emphysema) and other chronic lung diseases.
Data were extracted twice in a blinded fashion by different
extractors and later reconciled. The same person was allo-
cated to extract information on a case and its matched
control.
Deprivationdatawereobtainedby linking, via theNational
Postcode Directory,8 the GP post-code of each subject to
either a Lower Layer Super Output Area (average population
1500) within England and Wales or a Data Zone (average
population 750) within Scotland and thence to a country
specific Index of Multiple Deprivation (IMD) and its rank.9 We
used the 2004 index for England,10 the 2005 index for Wales11
and the 2006 index for Scotland.12 Using within country mid-
ranks, subjects were categorised according to whether their
primary care services were based in a more or less deprived
area of England, Scotland or Wales, as appropriate. The way
inwhich the IndexofMultipleDeprivation is calculateddiffers
between England, Scotland and Wales but all three measures
combine area level information on various aspects of
deprivation including income, employment, health and
education.9
The only variables included in the new analysis, but
obtained as part of the original study5e7 were sex, age of
asthmaonset,mentionof obesity ever andnumber of hospital
admissions for asthma in the 1 year and > 1e5 years prior.
Of the 532 cases, 112 (21%) died in hospital after the dayof
admission. Given the difference in index date definition
between cases and controls and the lack of information
recorded in the primary care notes during a period of hospital
admission, this could lead to bias; a bias that was not
adjusted for in the previous analysis. Any data relating to
drugs for the period of the index admission (including the day
of admission) was therefore removed/censored from the GP
record of the case and for an equivalent period from the GP
record of its matched control. A similar censoring process
was used to deal with the correction of errors in index dates
made after the photocopying of the primary care record. As
a result, the period of observation prior to the index datewas
shortened by more than 2 weeks for 52 matched pairs (10%),
more than 4 weeks for 28 matched pairs (5%), more than 2
months for 15 matched pairs (3%) and bymore than 6 months
for 5matched pairs (1%). Censoring was only implemented in
relation to information on drugs and the number of previous
hospital admissions for asthma.Statistical analysis
Data were analysed using conditional logistic regression and
the likelihood ratio test. The variables investigated included
six main classes of respiratory drugs (inhaled short-acting
beta2-agonists (SABA), inhaled long-acting beta2-agonists
(LABA), inhaled corticosteroids (ICS), oral corticosteroids,
antimuscarinics and methylxanthenes), two named drugs
(Salmeterol and Fenoterol), injected corticosteroids and
antibiotics. Fenoterol, an inhaled short-acting beta2-
agonist, was of interest, as case-control studies of severe
asthmatics conducted in New Zealand in the 1970s and 1980s
suggested that its prescription was associated with a higher
risk of asthma death.13 For each drug or class, two variables
were created representing any mention (yes/no) in the
Bronchodilator treatment and asthma death 551primary care record in the 2 and the > 2e6 months prior to
index date. Variables for LABA were further divided by the
presence/absence of a concomitantmention (1month either
sidebutprior to indexdate) of ICS.The full confoundermodel
included sex, age of asthma onset, ever mention of obesity,
mentionof COPD in thepast 5 years,mentionof other chronic
lung diseases in the past 5 years, previous admissions for
asthma in the past year and the> 1e5 years prior, othermain
respiratory drug classes, and deprivation rank within country.
Quantitative and ordinal variables (including deprivation
ranks) were treated in the full confounder model as contin-
uous. Deprivation rank group (less deprived, more deprived)
and age group (1e44, 45e64) were used tomodel and test for
interactions.
Our analysis makes the assumption that within a specified
period of observation (e.g. 2 months prior to index date),
odds ratios do not changewith time (e.g. are the same for the
1month prior and the> 1e2months prior), and are therefore
invariant to loss of data through censoring.Results
Among the 1064 study subjects only 55 (5.2%) were under
the age of 18 years. As reported previously5e7 and
described here in Table 1, cases and controls were similar
with respect to age (median 53 years interquartile range
(40e59) in both groups) and female sex (60.2% versus
63.5%) but cases had a significantly (p Z 0.013) earlier
median age of asthma onset (30 years (10e47) n Z 493
versus 33 years (13e49) n Z 502) and a higher proportion
had mention of obesity ever (30.6% versus 25.0%;Table 1 Descriptive statistics for cases and controls by age gro
Variable Total
Cases Cont
(N Z 532) (N Z
Deprivation
Scorea
England (most deprived): n (%) 238 (44.7) 240
England (least deprived): n (%) 110 (20.7) 107
Scotland (most deprived): n (%) 56 (10.5) 55
Scotland (least deprived): n (%) 26 (4.9) 28
Wales (most deprived): n (%) 72 (13.5) 69
Wales (least deprived): n (%) 30 (5.6) 33
Females: n (%) 320 (60.2) 338
Age at onset (yrs)b: Median
(interquartile range(IQR))
30 (10e47) 33
COPD mentioned in the last 5 years: n (%) 240 (45.1) 203
Other chronic lung disease
in the last 5 yearsc: n (%)
32 (6.0) 19
Obesity mentioned ever: n (%) 163 (30.6) 133
Any hospital admission for
asthma in the last yeard: n(%)
181 (34.0) 177
Any hospital admission for asthma
in the > 1 to 5 yearsd: n (%)
217 (40.8) 226
Note: Figures for age and age of onset may differ slightly from those
a Less Deprived Z deprivation rank (numerically) at or higher than
(numerically) lower than the mid-rank for the country.
b Information on age of onset missing for 39 cases and 30 controls.
c Other chronic lung diseases include bronchiectasis, aspergillosis, p
d Figures take account of length of index admission etc. through cep Z 0.037). Mention of other chronic lung diseases (6.0%
versus 3.6%) was also significantly (p Z 0.046) higher
among cases than controls as was mention of COPD (45.1%
versus 38.2%; p Z 0.010), with the latter association
differing significantly (p Z 0.020) between the 45e64 age
group (60.7% versus 48.9%) and the 1e44 year age group
(10.8% versus 14.9%). By contrast similar proportions were
mapped by GP post-code to the most deprived areas in
England (68.4% versus 69.2%), Scotland (68.3% versus
66.3%) and Wales (70.6% versus 67.6%) and even with
censoring, similar proportions of cases and controls had
mention of one or more asthma admissions in the past year
(34.0% versus 33.3%) and in the > 1e5 years prior (40.8%
versus 42.5%).
Table 2 displays odds ratios and 95% confidence intervals
adjusted firstly for sex alone and then using the full
confounder model. For the > 2e6 months prior, only SABA
were positively associated with asthma death and although
this association persisted in magnitude following full
adjustment it fell short of statistical significance at the 5%
level. A non-significant association of similar magnitude was
observed formention of SABA in the 2months prior, providing
a relatively consistent picture across the two time intervals.
Fenoterol was rarely prescribed but in the 2 months prior it
was mentioned in the notes of 4 cases but no controls.
There was a modest positive association between anti-
muscarinics mentioned in the 2 months prior and asthma
death which persisted in magnitude after full adjustment
but fell short of statistical significance at the 5% level.
By contrast, after full adjustment, oral corticosteroids,
injected corticosteroids and antibiotics mentioned in the 2
months prior were each associated with a significantlyup.
Age 1e44 years Age 45e64 years
rols Cases Controls Cases Controls
532) (N Z 166) (N Z 168) (N Z 366) (N Z 364)
(45.1) 80 (48.2) 75 (44.6) 158 (43.2) 165 (45.3)
(20.1) 29 (17.5) 38 (22.6) 81 (22.1) 69 (19.0)
(10.3) 20 (12.0) 22 (13.1) 36 (9.8) 33 (9.1)
(5.3) 11 (6.6) 9 (5.4) 15 (4.1) 19 (5.2)
(13.0) 17 (10.2) 17 (10.1) 55 (15.0) 52 (14.3)
(6.2) 9 (5.4) 7 (4.2) 21 (5.7) 26 (7.1)
(63.5) 92 (55.4) 110 (65.5) 228 (62.3) 228 (62.6)
(13e49) 10 (4e24) 13 (5e28) 42 (23e51) 44 (29e52)
(38.2) 18 (10.8) 25 (14.9) 222 (60.7) 178 (48.9)
(3.6) 2 (1.2) 2 (1.2) 30 (8.2) 17 (4.7)
(25.0) 33 (19.9) 27 (16.1) 130 (35.5) 106 (29.1)
(33.3) 48 (28.9) 55 (32.7) 133 (36.3) 122 (33.5)
(42.5) 67 (40.4) 73 (43.5) 150 (41.0) 153 (42.0)
previously published due to additional data cleaning.
the mid-rank for the country; More deprived Z deprivation rank
ulmonary TB and pulmonary fibrosis.
nsoring.
able 2 Odds ratios (95% confidence intervals) describing the association between asthma death and the prescriptiona of drugs in the 2 months and > 2e6 months before the
dex event.
rug class Mention in the past 2 months (n Z 1032) Mention in the > 2e6 months prior (n Z 1052)
Controls n (%)b
N Z 516
Adjusted for sex Adjusted for sex and
other factorsc
Controls n (%)b
N Z 526
Adjusted
for sex
Adjusted for sex and
other factorsc
OR (95% CI) OR (95% Ci) OR (95% CI) OR (95% CI)
haled short-acting
beta2-agonists
All 289 (56.0) 1.20 0.93e1.56 1.37 0.97e1.93 311 (59.1) 1.35* 1.05e1.75 1.40 0.99e1.99
haled long-acting
beta2-agonists
All 100 (19.4) 0.96 0.69e1.32 0.89 0.61e1.30 115 (21.9) 1.16 0.86e1.57 1.08 0.76e1.53
Salmeterol 98 (19.0) 0.89 0.63e1.24 0.82 0.56e1.20 114 (21.7) 1.12 0.83e1.52 1.02 0.72e1.45
All with ICSd 86 (16.7) 0.98 0.70e1.38 0.92 0.61e1.37 107 (20.3) 1.14 0.83e1.56 1.05 0.73e1.51
All without ICSd 14 (2.7) 0.80 0.36e1.81 0.75 0.32e1.78 8 (1.5) 1.39 0.56e3.48 1.39 0.53e3.65
ntimuscarinics All 130 (25.2) 1.34* 1.01e1.77 1.35 0.94e1.95 148 (28.1) 1.30 0.99e1.70 1.10 0.78e1.55
orticosteroids All 346 (67.1) 0.79 0.61e1.03 0.52*** 0.36e0.73 347 (66.0) 1.27 0.98e1.64 1.00 0.70e1.43
Inhaled (ICS) 241 (46.7) 0.99 0.77e1.28 0.86 0.61e1.22 298 (56.7) 1.13 0.89e1.45 0.85 0.60e1.20
Oral 258 (50.0) 0.86 0.67e1.09 0.65** 0.48e0.88 253 (48.1) 1.16 0.91e1.48 0.98 0.72e1.33
Injected 21 (4.1) 0.41* 0.18e0.92 0.34* 0.14e0.81 27 (5.1) 1.42 0.87e2.33 1.47 0.84e2.58
ethylxanthines All 55 (10.7) 1.14 0.77e1.69 1.13 0.73e1.73 72 (13.7) 1.11 0.77e1.60 0.93 0.62e1.38
ntibiotics All 251 (48.6) 0.79 0.62e1.01 0.68* 0.50e0.92 250 (47.5) 1.10 0.85e1.42 0.92 0.67e1.26
< 0.05, **p < 0.01, ***p < 0.001.
ote: Due to censoring and the exclusion of one matched pair mapped to different countries based on GP post-code, analyses for the 2 months prior and the > 2e6 months prior were
ased on 516 and 526 matched pairs respectively.
a Prescription Z mention of drug in primary care notes including computer printouts, referral letters, hospital discharge and outpatient letters.
b Percentage of controls prescribed drug.
c Additionally adjusted for age of asthma onset (including missings), mention of obesity ever, number of hospital admissions in the past year and > 1e5 years prior, mention of COPD in
e past 5 years and mention of other chronic lung disease in the past 5 years, mention/prescription in the relevant time period of other asthma drug classes (inhaled corticosteroids, oral
orticosteroids, inhaled short-acting beta2-agonists, inhaled long-acting beta2-agonists, antimuscarinics and methylxanthines) as appropriate and for any linear trend in deprivation rank
ithin country.
d Mention of inhaled corticosteroids within 1 month either side of a mention of inhaled long-acting beta2-agonists but prior to index date; comparison group e no mention of inhaled long-
cting beta2-agonists. Final adjustment includes adjustment for mention/prescription of inhaled corticosteroids in the 2 months or > 2e6 months prior as appropriate.
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Bronchodilator treatment and asthma death 553lower risk of asthma death. However these three associa-
tions were not independent and when adjusted for each
other (an extension of the full confounder model), the
association with oral steroids became more consistent with
a chance effect (OR Z 0.76 (95% confidence interval 0.55
to1.04)), while associations with antibiotics (OR Z 0.67
(0.49e0.91)) and injected steroids (ORZ 0.33 (0.14e0.80))
were little changed.
Even with full adjustment, there was no evidence of an
overall association between LABA and asthmadeathwhether
mentioned in the 2 months (OR Z 0.89 (95% confidence
interval 0.61 to 1.30)) or > 2e6 months prior (OR Z 1.08
(0.76e1.53)). Where LABA were mentioned in the primary
care notes it was usual to find a mention of ICS within 1
month. Such evidence of concomitant prescribing was found
in 86% of controls with a mention of LABA in the 2 months
prior and 93% of controls with mention of LABA in the > 2e6
months prior. Fully adjusted odds ratios for LABA with and
without concomitant mention of ICS were 0.92 (0.61e1.37)
and 0.75 (0.32e1.78) respectively for the 2month period and
1.05 (0.73e1.51) and 1.39 (0.53e3.65) for the > 2e6 month
period but for both periods these differences were not
statistically significant (p Z 0.671 and p Z 0.579
respectively).
Table 3 displays odds ratios, and 95% confidence inter-
vals adjusted for the full confounder model, extended to
include age group interactions with sex, COPD and other
chronic lung diseases. For the > 2e6 month period, odds
ratios for Salmeterol differed significantly between the
1e44 and 45e64 year age groups as did the odds ratios for
all LABA which were 0.63 (0.34e1.15) and 1.35 (0.90e2.03)
respectively. There was no evidence of any similar age
interaction with Salmeterol or all LABA when mentioned in
the 2 months prior.
Table 4 shows the results for the analysis of deprivation
ranks, within each country. In the 2 months prior odds
ratios for Salmeterol differed significantly across the 6
categories defined by country and within country depriva-
tion rank. This finding appeared to be due to differences
between deprivation groups within countries (p Z 0.023;
df Z 3) rather than differences between countries
(pZ 0.389; dfZ 2) but given the lack of consistency in the
direction of association within countries, it provides no
coherent evidence of effect modification by deprivation.
Odds ratios for mention of SABA in the > 2e6 months
prior provided little evidence of a positive association with
mortality within Scotland or Wales but within England, odds
ratios for the less and more deprived areas were 2.72
(1.48e5.00) and 1.56 (0.97e2.52) respectively. However
differences across the 6 groups appeared to be due to
differences between countries (p Z 0.003; df Z 2) rather
than between deprivation groups within countries (p Z
0.437; df Z 3). Odds ratios for LABA mentioned in the
> 2e6 months prior, exhibited a similar pattern to SABA,
although for this variable the difference across all six
groups was not statistically significant at the 5% level.Discussion
In this fresh analysis of the ADCCS, we have used a dataset
which has a higher level of detail and fewer potential biasesthan that used for the original report. Using different time
references we have found, overall, a similar pattern of
associations to those found by the previous analysis. In
particular we found no evidence of any overall association
between LABA and asthma death but some evidence that
antibiotics and oral steroids when mentioned close to the
index date, were associated with a lower risk of asthma
death. A similar association with injected steroids is a new
finding. Despite similarities with the original results, there
are also material differences especially in terms of age
group interactions which in the earlier report were only
adjusted for sex. The results in this paper should therefore
be viewed as replacing and adding to those previously
published for the period 3 months prior to the index date.
Long-acting beta2-agonists (including salmeterol)
In this British study of severe asthmatics, there was no
evidence that LABA, whether mentioned in the 2 or > 2e6
months prior, was associated with asthma mortality. Even
for the > 2e6 month period, mention of LABA though
consistent with up to a 53% higher risk of asthma death was
also consistent with as much as a 24% lower risk (based on
the upper and lower 95% confidence limits). This makes the
finding of a significant age interaction in the > 2e6 months
prior difficult to interpret especially as there was no
significant odds ratio in either the 1e44 year or the 45e64
year age group.
There was no evidence that any association between
LABA and mortality differed in a consistent fashion between
those attending a GP surgery in a more or less deprived area.
However our deprivation measures were somewhat limited,
being neighbourhood rather than person specific, based on
GP rather than patient post-code and relying on information
which post-dated our study period e.g. Index of Multiple
Deprivation for England 2004.
It has been suggested that any positive association
between LABA and mortality might be reduced in the
presence of ICS.2,14 In our study mention of LABA without
a concomitant mention of ICS was uncommon. It has been
suggested that this explains the lack of association between
LABA and mortality reported in our previous analysis of this
case-control study. However, it also means that if a modi-
fying effect of ICS exists we have little statistical power to
detect it. Odds ratios for LABA with and without ICS (Table
2) add little to the debate as they do not provide a consis-
tent pattern across the two time windows.Inhaled short-acting beta2-agonists
In line with other studies15e18 we found some evidence of
a higher risk of asthma death associated with any mention
of SABA in the > 2e6 months prior, an association which did
not appear to be explained by our adjustment for potential
confounding factors. Final adjusted odds ratios for mention
in the 2 and > 2e6 months prior were similar in magnitude,
though somewhat lower than the adjusted odds ratio of
2.05 (1.26e3.33) reported by our previous analysis of the
> 1e5 years prior.5
There was no evidence of a modifying effect of age or
background levels of deprivation (basedonGPpost-code) but
Table 3 Age-group specific adjusteda odds ratios (95% confidence intervals) describing the association between asthma death and the prescriptionb of drugs in the 2 months
and > 2 to 6 months before index event.
Drug/Drug class Age group Mention in the past 2 months (n Z 1032) Mention in the > 2 to 6 months (n Z 1052)
Cont % (n/N)c
N Z 516
OR (95% CI) Test for age
interaction
Cont % (n/N)c
N Z 526
OR (95% CI) Test for age
interaction
Short-acting
beta2-agonists (inhaled)
1e44 58.8 (97/165) 1.51 (0.89e2.57) P Z 0.674 58.3 (98/168) 1.27 (0.75e2.15) P Z 0.683
45e64 54.7 (192/351) 1.33 (0.90e1.97) 59.5 (213/358) 1.43 (0.96e2.13)
Long-acting
beta2-agonists (inhaled)
1e44 23.0 (38/165) 0.89 (0.48e1.62) P Z 0.986 27.4 (46/168) 0.63 (0.34e1.15) P Z 0.028
45e64 17.7 (62/351) 0.89 (0.57e1.40) 19.3 (69/358) 1.35 (0.90e2.03)
Salmeterol (inhaled) 1e44 23.0 (38/165) 0.77 (0.41e1.42) P Z 0.792 27.4 (46/168) 0.56 (0.30e1.04) P Z 0.016
45e64 17.1 (60/351) 0.85 (0.53e1.35) 19.0 (68/358) 1.32 (0.87e1.99)
Antimuscarinics 1e44 22.4 (37/165) 1.19 (0.65e2.16) P Z 0.700 22.0 (37/168) 0.94 (0.50e1.77) P Z 0.636
45e64 26.5 (93/351) 1.35 (0.89e2.05) 31.0 (111/358) 1.11 (0.76e1.64)
Corticosteroids
(inhaled)
1e44 47.3 (78/165) 0.83 (0.48e1.42) P Z 0.891 49.4 (83/168) 1.03 (0.62e1.72) P Z 0.331
45e64 46.4 (163/351) 0.86 (0.59e1.27) 60.1 (215/358) 0.79 (0.53e1.16)
Corticosteroids (oral) 1e44 48.5 (80/165) 0.46 (0.28e0.77) P Z 0.088 43.5 (73/168) 0.81 (0.50e1.33) P Z 0.337
45e64 50.7 (178/351) 0.76 (0.54e1.07) 50.3 (180/358) 1.07 (0.75e1.53)
Antibiotics 1e44 46.7 (77/165) 0.63 (0.38e1.04) P Z 0.798 47.6 (80/168) 0.61 (0.35e1.05) P Z 0.067
45e64 49.6 (174/351) 0.68 (0.48e0.98) 47.5 (170/358) 1.09 (0.75e1.58)
Note: Due to censoring and the exclusion of one matched pair mapped to different countries based on GP post-code, analyses for the 2 months prior and the > 2e6 months prior were
based on 516 and 526 matched pairs respectively.
a Adjusted for sex, an age group interaction with sex, age of asthma onset (including missings), mention of obesity ever, number of hospital admissions in the past year and > 1e5 years
prior, mention of COPD in the past 5 years and mention of other chronic lung disease in the past 5 years (including age group interactions with COPD and other chronic lung diseases),
mention/prescription in the 2 months prior of other asthma drug classes (inhaled corticosteroids, oral corticosteroids, inhaled short-acting beta2-agonists, inhaled long-acting beta2-
agonists, antimuscarinics and methylxanthines) as appropriate and for any linear trend in deprivation rank within country.
b Prescription Z mention of drug in primary care notes including computer printouts, referral letters, hospital discharge and outpatient letters.
c Within age group, percentage of controls prescribed drug.
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Table 4 Adjusteda odds ratios for asthma death associated with the prescriptionb of beta2-agonists in the 2 months and > 2 to 6 months prior by high (less deprived) vs. low
(more deprived) deprivation rank within country.
Drug/Drug class Country Deprivation
Scorec
Mentioned in the past 2 months Mentioned in the > 2 to 6 months prior
Cont %d (n/N) OR (95% CI) Test for differences
in OR across groups
(df Z 5)
Cont %d (n/N) OR (95% CI) Test for differences
in OR across groups
(df Z 5)
Short-acting
beta2-agonists
(inhaled)
England Less Deprived 55.3 (57/103) 1.87 (0.99e3.52) P Z 0.069 47.7 (51/107) 2.72 (1.48e5.00) P Z 0.015
More Deprived 58.4 (136/233) 1.50 (0.94e2.39) 62.0 (147/237) 1.56 (0.97e2.52)
Scotland Less Deprived 59.3 (16/27) 0.70 (0.22e2.23) 64.3 (18/28) 1.04 (0.28e3.83)
More Deprived 47.2 (25/53) 1.45 (0.62e3.44) 59.3 (32/54) 0.87 (0.39e1.93)
Wales Less Deprived 51.5 (17/33) 2.81 (0.92e8.58) 75.8 (25/33) 0.48 (0.14e1.64)
More Deprived 56.7 (38/67) 0.58 (0.27e1.23) 56.7 (38/67) 0.72 (0.33e1.55)
Long-acting
beta2-agonists
(inhaled)
England Less Deprived 20.4 (21/103) 1.09 (0.51e2.32) P Z 0.077 17.8 (19/107) 2.08 (0.99e4.37) P Z 0.205
More Deprived 18.9 (44/233) 1.01 (0.61e1.69) 21.1 (50/237) 1.19 (0.71e2.00)
Scotland Less Deprived 25.9 (7/27) 0.21 (0.04e1.01) 32.1 (9/28) 0.54 (0.15e1.95)
More Deprived 18.9 (10/53) 0.99 (0.38e2.60) 27.8 (15/54) 0.78 (0.32e1.95)
Wales Less Deprived 18.2 (6/33) 1.77 (0.52e6.05) 30.3 (10/33) 0.49 (0.14e1.65)
More Deprived 17.9 (12/67) 0.27 (0.08e0.88) 17.9 (12/67) 0.81 (0.31e2.11)
Salmeterol
(inhaled)
England Less Deprived 20.4 (21/103) 0.95 (0.44e2.06) P Z 0.044 17.8 (19/107) 1.94 (0.92e4.07) P Z 0.224
More Deprived 18.9 (44/233) 0.96 (0.57e1.61) 21.1 (50/237) 1.14 (0.68e1.92)
Scotland Less Deprived 25.9 (7/27) 0.21 (0.04e0.99) 32.1 (9/28) 0.54 (0.15e1.93)
More Deprived 18.9 (10/53) 0.90 (0.34e2.43) 27.8 (15/54) 0.78 (0.31e1.93)
Wales Less Deprived 15.2 (5/33) 1.64 (0.45e6.00) 30.3 (10/33) 0.49 (0.14e1.65)
More Deprived 16.4 (11/67) 0.16 (0.04e0.67) 16.4 (11/67) 0.66 (0.24e1.84)
Note: Due to censoring and the exclusion of one matched pair mapped to different countries based on GP post-code, analyses for the 2 months prior and the> 2e6 months prior were based
on 516 and 526 matched pairs respectively.
a Adjusted for sex, age of asthma onset (including missings), mention of obesity ever, number of hospital admissions in the past year and > 1e5 years prior, mention of COPD in the past 5
years and mention of other chronic lung disease in the past 5 years, and mention/prescription in the > 2e6 months prior of other asthma drug classes (inhaled corticosteroids, oral
corticosteroids, inhaled short-acting beta2-agonists, inhaled long-acting beta2-agonists, antimuscarinics and methylxanthines) as appropriate.
b Prescription Z mention of drug in primary care notes including computer printouts, referral letters, hospital discharge and outpatient letters.
c Less Deprived Z deprivation rank (numerically) at or higher than the mid-rank for the country; More deprived Z deprivation rank (numerically) lower than the mid-rank for the
country.
d Percentage of controls prescribed drug.
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556 B.K. Butland et al.we unexpectedly found evidence in support of a modifying
effect of ‘country’. This comparison was not postulated
a priori and should be viewed with caution. It may be due to
chance or reflect real regional differences in: prescribing;
record keeping (due to the use of ‘mentions’ rather than
prescriptions); access to both primary and secondary care;
and/or patient behaviour in terms of compliance and the
severity threshold for seeking medical treatment.
Antimuscarinics and methylxanthines
Mention of antimuscarinics (predominantly ipratropium
bromide) was associated with a higher risk of asthma death
in the 2 months prior, an association that persisted in
magnitude after full adjustment. Some other indications of
a positive association between asthma death and ipra-
tropium bromide, or the regular use of all antimuscarinics
have been reported from the General Practice Research
Database18,19 and a small case-control study.20 However, as
suggested in these studies, such associations may result
from confounding by co-morbidity with COPD or by asthma
severity. The latter may explain our findings as, based on
BTS guidelines,21 antimuscarinics were only prescribed to
those with very severe asthma or whose asthma was not
adequately controlled by high-dose ICS (Step 4).
We found no evidence of an association between meth-
ylxanthines and asthma death, even though, like anti-
muscarinics, these drugs were also reserved until Step 4.21
Inhaled corticosteroids
Regular use of ICS is well established as beneficial in pre-
venting asthma exacerbations22 and is associated with
a lower risk of asthma admissions.23,24 However we found
little evidence of an association between asthma death and
ICS, although in the 2 months, > 2e6 months and in the
> 1e5 years prior,5 odds ratios, though non-significant,
were of similar magnitude (0.86, 0.85, 0.86 respectively).
Oral and injected corticosteroids
Oral corticosteroids tend to be prescribed as a short ‘rescue’
course in response to an acute attack, or as maintenance
(BTS Step 5) among severe asthmatics.21 The inverse asso-
ciation observed both for oral corticosteroids and for injec-
ted corticosteroids in the 2 but not the > 2e6 months prior
may therefore indicate the benefit of appropriate treatment
in the immediate lead up to the index event.
Antibiotics
Mention of antibiotics in the 2 months prior was associated
with a 32% lower risk of asthma death and although there
was no evidence of an association in the > 2e6 months
prior, the former was consistent with previously published
results for the > 1e5 year period (ORZ 0.59).5 This merits
further investigation because there is little evidence in the
literature to indicate whether or not antibiotics should be
prescribed in the treatment of acute asthma without
evidence of bacterial infection25 and current guidelines
clearly warn against over-use.Study limitations
In this study we have gone to great lengths to obtain good
quality data and to adjust for potential bias. Nevertheless,
the quality and completeness of the information contained
in the general practitioner notes was not within our control,
leading us to base our drug variables on mention in the GP
notes (Yes or No). Mention is not the same as prescription
but in common with prescription is dependent on the level
of use of primary and secondary care services. How to
disentangle use leading to prescription or use increasing the
likelihood of picking up a mention of a prescribed drug is
problematic but to some extent will be adjusted for by the
inclusion of other asthma drugs, prior hospital admissions
and co-morbidity in our final model. As in all observational
studies adjustment for confounding is important and in this
new analysis we have introduced adjustment for depriva-
tion in addition to markers of asthma severity and co-
morbidity. However, the possibility of confounding by other
factors cannot be discounted. Finally given that we present
results for two time periods it is important that we do not
place too much emphasis on unexpected significant results
which may be the spurious outcome of multiple testing.
Conclusion
While associations of oral corticosteroids, injected cortico-
steroids and antibiotics with a lower risk of asthma deathmay
simply indicate the benefits of appropriate medication for an
acute asthma episode or infective exacerbation, the
geographic pattern of results observed for inhaled short-
acting beta2-agonists though unexpected may point to
differences in regional prescribing patterns andhealth service
provision/utilisation. In a population of severe asthmatics in
whom long-acting beta2-agonists and inhaled corticosteroids
appeared to be commonly prescribed concomitantly, there
was no evidence overall that long-acting beta2-agonists were
associated with increased risk of asthma death.Acknowledgements
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